These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8665560)

  • 1. Color vision in Parkinson's disease: missing influence of amantadine sulphate.
    Büttner T; Kuhn W; Müller T; Patzold T; Przuntek H
    Clin Neuropharmacol; 1995 Oct; 18(5):458-63. PubMed ID: 8665560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Dopa improves colour vision in Parkinson's disease.
    Büttner T; Kuhn W; Patzold T; Przuntek H
    J Neural Transm Park Dis Dement Sect; 1994; 7(1):13-9. PubMed ID: 8579766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease.
    Pinter MM; Birk M; Helscher RJ; Binder H
    J Neural Transm (Vienna); 1999; 106(7-8):711-24. PubMed ID: 10907729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of apomorphine on visual functions in Parkinson's disease.
    Büttner T; Müller T; Kuhn W
    J Neural Transm (Vienna); 2000; 107(1):87-94. PubMed ID: 10809406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities in color vision and contrast sensitivity in Parkinson's disease.
    Price MJ; Feldman RG; Adelberg D; Kayne H
    Neurology; 1992 Apr; 42(4):887-90. PubMed ID: 1565248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Color discrimination deficits in Parkinson's disease are related to cognitive impairment and white-matter alterations.
    Bertrand JA; Bedetti C; Postuma RB; Monchi O; Génier Marchand D; Jubault T; Gagnon JF
    Mov Disord; 2012 Dec; 27(14):1781-8. PubMed ID: 23147270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress of visual dysfunction in Parkinson's disease.
    Müller T; Woitalla D; Peters S; Kohla K; Przuntek H
    Acta Neurol Scand; 2002 Apr; 105(4):256-60. PubMed ID: 11939937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distorted color discrimination in 'de novo' parkinsonian patients.
    Büttner T; Kuhn W; Müller T; Patzold T; Heidbrink K; Przuntek H
    Neurology; 1995 Feb; 45(2):386-7. PubMed ID: 7854545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.
    Kim YE; Yun JY; Yang HJ; Kim HJ; Gu N; Yoon SH; Cho JY; Jeon BS
    PLoS One; 2012; 7(11):e48890. PubMed ID: 23185280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
    Nousiainen I; Kälviäinen R; Mäntyjärvi M
    Ophthalmology; 2000 May; 107(5):884-8. PubMed ID: 10811079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor impairment influences Farnsworth-Munsell 100 Hue test error scores in Parkinson's disease patients.
    Müller T; Meisel M; Russ H; Przuntek H
    J Neurol Sci; 2003 Sep; 213(1-2):61-5. PubMed ID: 12873756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
    Ory-Magne F; Corvol JC; Azulay JP; Bonnet AM; Brefel-Courbon C; Damier P; Dellapina E; Destée A; Durif F; Galitzky M; Lebouvier T; Meissner W; Thalamas C; Tison F; Salis A; Sommet A; Viallet F; Vidailhet M; Rascol O;
    Neurology; 2014 Jan; 82(4):300-7. PubMed ID: 24371304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amantadine sulfate infusion effect on N30 somatosensory evoked potentials in Parkinson's disease.
    Bostantjopoulou S; Katsarou Z; Georgiadis G; Zafiriou D; Kazis A
    Clin Neuropharmacol; 2002; 25(2):115-8. PubMed ID: 11981240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations.
    Brenner M; Haass A; Jacobi P; Schimrigk K
    J Neurol; 1989 Mar; 236(3):153-6. PubMed ID: 2709063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease.
    Diederich NJ; Raman R; Leurgans S; Goetz CG
    Arch Neurol; 2002 Aug; 59(8):1249-52. PubMed ID: 12164720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-perception and determinants of color vision in Parkinson's disease.
    Brandt AU; Zimmermann HG; Oberwahrenbrock T; Isensee J; Müller T; Paul F
    J Neural Transm (Vienna); 2018 Feb; 125(2):145-152. PubMed ID: 29143216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease.
    Müller T; Kuhn W; Büttner T; Eising E; Coenen H; Haas M; Przuntek H
    J Neurol; 1998 Oct; 245(10):659-64. PubMed ID: 9776465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor visual discrimination and visual hallucinations in Parkinson's disease.
    Diederich NJ; Goetz CG; Raman R; Pappert EJ; Leurgans S; Piery V
    Clin Neuropharmacol; 1998; 21(5):289-95. PubMed ID: 9789709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of color perception in individuals addicted to narcotic substances in the Farnsworth-Munsell 100-Hue test].
    Nadolska K; Goś R
    Med Pr; 2016 Dec; 67(6):777-785. PubMed ID: 28005086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.